Mondias names Jamil Samsatly as Chief Scientific Officer
MONTREAL, March 13, 2019 /CNW/ – Mondias Naturals Inc. (“Mondias” or the “Company”) (TSXV: NHP) is pleased to announce the appointment of Jamil Samsatly as Chief Scientific Officer. Mr. Samsatly has been conducting research for the past two years as a consultant on the Company’s CELEXT07, a bio-defense stimulant that has the potential of becoming a superior eco-friendly alternative to synthetic fungicides, as part of a collaboration project with McGill University.
Mr. Samsatly is currently completing his Ph.D. at McGill University and has broad experience in sustainable agriculture, healthy agri-food systems and molecular biotechnology. He previously received an M.Sc. and B.Sc. in biology and plant pathology from the American University of Beirut. Working as a researcher for almost 10 years at well-recognized international institutions such as the International Center for Agricultural Research in the Dry Areas (ICARDA), Institut National de la Recherche Agronomique – Avignon, the American University of Beirut and McGill University has allowed him to fully understand the challenges faced by agriculture globally, and to develop a deep understanding of applied research and the types of products that are needed in sustainable agriculture. Mr. Samsatly is well recognized in his field of expertise, having published in leading scientific journals and contributed to building a broader picture of plant pathology and host-pathogen interactions, with a special focus on the role of antioxidants and vitamins.
“We are very pleased that Mr. Samsatly has agreed to play a bigger role with Mondias as our Chief Scientific Officer,” said Jean-Philippe Gravel, Chief Executive Officer of Mondias. “His dedicated research on our CELEXT07 bio-defense stimulant has been promising in bringing this product even closer to market. We strongly believe that his knowledge and research expertise in the development of bio-controls and bio-fertilizers for cannabis and other organic agriculture production systems will greatly assist Mondias in fulfilling its growth potential and achieve commercial success.”
About Mondias Natural Products Inc.
Mondias specializes in the commercialization and development of evidence-based botanical products for the health care, bio-agriculture and organic markets. The company sells both oral and topical botanical agents to help manage unmet medical needs through its Holizen Laboratories division. Mondias is also developing botanical-based specialty fertilizers for use on household plants, lawns and golf courses and in urban gardens, nurseries and greenhouses, in collaboration with McGill’s Faculty of Agricultural and Environmental Sciences.
For more information, visit: mondias.ca.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the success of this joint venture, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.